Combination of multiple therapies is a common approach to treating patients with unresectable hepatocellular carcinoma (uHCC).
The impact of immune checkpoint inhibitors (ICIs) on prognosis in uHCC patients treated with transarterial chemoembolization (TACE) and lenvatinib remains unclear.
